in the absence of a submission from the holder of the marketing authorisation
sacituzumab govitecan (Trodelvy®) is not recommended for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice292KB (PDF)
Medicine details
- Medicine name:
- sacituzumab govitecan (Trodelvy®)
- SMC ID:
- SMC2916
- Indication:
As monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 March 2026